PhageEconomics©

PhageEconomics - Public Market and Funding Monitor
Warning: PhageEconomics is an information product only, not financial advice.

Every price, risk profile, projection, funding note, and company paragraph on this page is for research monitoring. It must never be treated as an instruction to buy, sell, hold, subscribe, short, hedge, or finance any security or private round.

Read the full disclaimer

PhageEconomics

Active phage exposure only

This dashboard created by The Phage Therapy tracks publicly traded companies that still have a live, current, and identifiable relationship with bacteriophage therapy, phage-derived antimicrobial platforms, or commercial bacteriophage products. Old tickers, delisted stories, bankrupt shells, and companies that pivoted away from phage work are deliberately excluded from the investable watchlist. Market curves, price checks, funding signals, and new-listing signals refresh automatically when public browser-accessible endpoints are reachable; newly detected financings and listings are stored as verification candidates before they enter the verified dataset.

Covered equities 0 current public-market exposures
Direct phage names 0 human or human-adjacent phage focus
Average risk 0/100 microcap biology deserves caution
Local refresh -- automatic feeds refresh when accessible
Loading public market summary...

Clean market curve

Native SVG price and volume curve drawn by PhageEconomics. Hover the curve for the nearest date, price, and volume. No external chart widget, iframe, screenshot, third-party chart image, or bundled price dataset is embedded.

-- Select a market range
Loading clean market curve...
Company Ticker Current phage link Status One-year context Risk Next things to watch

Company-specific risk dossiers

The risk score is not a price forecast. It is a structured warning score based on liquidity, concentration, development stage, commercial proof, financing pressure, listing quality, and how much of the public company is actually tied to bacteriophage economics.

Curated phage-economics ecosystem

This directory is intentionally selective. It does not try to list every laboratory, hospital group, legacy ticker, or dormant brand. It keeps companies and commercial actors where public information is specific enough to support a useful market note, funding note, or diligence question.

Automatic ecosystem monitor

This live panel checks public news signals for the curated ecosystem. It does not reproduce article text; it only shows source, date, and links for manual verification.

Web search
The ecosystem monitor will load when this tab opens.

Automatic new-listing monitor

This panel watches for public-market entry signals such as IPO, listing, Nasdaq, NYSE, Euronext, TSXV, KOSDAQ, reverse merger, de-SPAC, and exchange bulletin language connected to bacteriophage companies. Automatic news discovery can surface false positives, so every result needs manual confirmation before it enters the equity universe.

Web search
The listing monitor will load when this tab opens.

Automatically added listing candidates

New public-listing signals found by the automatic monitor are added here and stored locally. They remain candidates until a primary exchange notice, filing, or company release confirms the listing.

Private companies that could matter next

These are not public stocks today. They are included because successful financing, clinical progress, acquisition, or a future listing could reshape the public phage universe.

Funding rounds, grants, and strategic capital

Closed rounds are shown at 100%. Milestone-based contracts show the amount publicly awarded against the maximum disclosed ceiling. The percentage is therefore a funding-progress indicator, not a probability of success.

Company Capital type Public amount Progress Use of proceeds Source

Automatically added funding candidates

New funding signals detected by the automatic monitor are added here and stored locally. Amount and percentage stay pending until the linked source confirms a numeric round, grant, contract, or financing ceiling.

Automatic funding monitor

Web search
The funding monitor will load when this tab opens.
Market insights

Original market note

Market analysis workspace

This notebook is reserved for market theses, follow-up questions, and manual annotations. Notes are stored locally in this browser.

Sources and coverage rules

The initial dataset was checked on July 24, 2026. Public companies without current phage relevance, former phage names that pivoted away, bankrupt shells, and delisted historical names are not part of the active equity screen.

    Excluded or legacy names

    Comments

    Post a Comment

    Most Consulted Articles

    Bacteriophages Disarm Inflammation-Associated E. coli Without Erasing the Gut Microbiome in IBD

    Image
    Inflammatory bowel disease is usually described through the language of immune dysregulation, chronic inflammation and genetic susceptibility. Yet an increasingly important part of the disease may lie in a more dynamic layer of biology: not simply which microorganisms inhabit the intestine, but what particular bacterial populations are doing inside it. A new study from McMaster University pushes this idea toward a striking therapeutic possibility. Instead of broadly eliminating bacteria associated with disease, bacteriophages may be used to selectively suppress the bacterial traits that help drive inflammation. McMaster researchers, from left, Kyle Jackson, Zeinab Hosseinidoust and Elena Verdu, have found a way to disarm harmful gut bacteria using precision viruses, opening the door to more personalized treatments for inflammatory bowel disease. (Georgia Kirkos, McMaster University) The work, published in Science Translational Medicine and highlighted on the journal’s cover, emerged...
    Read more

    History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

    Image
    Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
    Read more

    The Phage Therapy in the spotlight !

    Image
    Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
    Read more

    Groundbreaking achievement : Phagos raises €25m to end bacterial disease

    Image
     Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
    Read more

    🌐 PhageAtLabs® — a global interactive mapping of academic laboratories in phage research.

    Image
    🌐 PhageAtLabs® — a global interactive mapping of academic laboratories in phage research. Take part in the project here: https://lnkd.in/e-csNChu   Support the project here: https://ko-fi.com/thephagetherapy PhageAtLabs® is currently under active development by The Phage Therapy team, with the aim of launching the platform this summer. At this stage, we are actively collecting information to ensure the platform is as complete and accurate as possible. For this reason, we kindly encourage you to share this form as widely as possible with laboratories, research groups, and colleagues working on bacteriophages that you know. This initiative is dedicated to building an interactive global map of academic laboratories and research groups working on bacteriophages. The goal is to create a structured and continuously updated database that brings together universities, institutes, and research teams involved in phage science worldwide. While similar initiatives exist in the broader ecosy...
    Read more